This post was originally published on this site
(Reuters) – A U.S. Centers for Disease Control and Prevention advisory panel on Thursday recommended a booster shot of the Pfizer (NYSE:PFE) and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions.
The vote by the group, following U.S. Food and Drug Administration authorization, clears the way for a booster rollout to begin as soon as this week for millions of people who had their second dose at least six months ago.
